References

Acupuncture Allergies Alzheimer's Disease Androgen Anxiety Disorders Asthma Atherosclerosis Attention Deficit Hyperactivity Disorder Bacterial Vaginosis Biofeedback Bipolar Disorder Birth Control Pills Blood Donation and Transfusion Breast Augmentation and Reduction Breast Cancer Breastfeeding Breast Reconstruction Caregiving Cervical Cancer Chiropractic Chlamydia Cholesterol Chronic Fatigue Syndrome Clinical Trials Colon Cancer Contraception Depression Diabetes Dry Eye Syndrome Eating Disorders Endometriosis Epilepsy Estrogen Fibroids Fibromyalgia Fitness Flu/Colds Gastroesophageal Reflux Disease (GERD) Genetic Testing Genital Herpes Glaucoma Gonorrhea Health Insurance Heart Disease Hepatitis High Blood Pressure HIV/AIDS Homeopathy Human Papillomavirus Hypnosis Hysterectomy Incontinence Infertility Irritable Bowel Syndrome Legal Health Tools Liposuction Lung Cancer Lupus Macular Degeneration Medication Safety Menopause Menstrual Disorders Metabolic Syndrome Migraine Multiple Sclerosis Naturopathy Nonsurgical Aesthetic Procedures Nutrition Obesity Ocular Allergies Oral Health Osteoarthritis Osteopathic Medicine Osteoporosis Ovarian Cancer Overactive Bladder Pain Management Pelvic Organ Prolapse Pelvic Pain Peripheral Arterial Disease Polycystic Ovary Syndrome Pregnancy Premenstrual Syndrome Preparing for Surgery Progesterone Rheumatoid Arthritis Schizophrenia Scleroderma Sexual Dysfunction Sinusitis Sjogren's Syndrome Skin Cancer Skin Health Sleep Disorders Smoking Stress Stroke Substance Abuse Tai Chi Teen Health Thyroid Disorders Trichomoniasis Urinary Tract Conditions Urinary Tract Infection Uterine Cancer Varicose Veins Violence Against Women Vulvodynia Weight Management Yeast Infections Yoga

"Reclast receives US FDA approval as first and only once-yearly treatment for women with postmenopausal osteoporosis." Novartis Pharmaceuticals Corporation. Press release, August 17, 2007.

U.S Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S Department of Health and Human Services, Office of the Surgeon General, 2004.

"Prevention: Calcium & Vitamin D." National Osteoporosis Foundation. http://www.nof.org. Accessed November 18, 2004.

"Prevention: Exercise for Healthy Bones." National Osteoporosis Foundation. http://www.nof.org. Accessed November 18, 2004.

"Medications to Prevent & Treat Osteoporosis." National Osteoporosis Foundation. http://www.nof.org. Accessed November 18, 2004.

"Boning Up on Osteoporosis." U.S. Food and Drug Administration. Updated April 2004. http://www.fda.gov. Accessed November 18, 2004.

"Osteoporosis: What Is It?" National Osteoporosis Foundation. http://www.nof.org. Accessed November 18, 2004.

"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Prevention And Treatment of Postmenopausal Osteoporosis: 2001 Edition, with Selected Updates For 2003." http://www.aace.com. Accessed Novwember 18, 2004.

"Osteoporosis Overview." National Institutes of Health Osteoporosis and Related Bone Diseases--National Resource Center. Revised January 2003. http://www.osteo.org. Accessed Njovember 18, 2004.

"First Fracture May Be a Warning Sign." American Academy of Orthopaedic Surgeons. October 2002. http://orthoinfo.aaos.orgAccessed November 18, 2004.

"Vertebral Compression Fractures in the Elderly." American Academy of Family Physicians. January 1, 2004. http://www.aafp.orgAccessed November 18, 2004.

FDA Plans to Evaluate Results of Women's Health Initiative Study for Estrogen Therapy. U.S. Food and Drug Administration. FDA Talk Paper. March 2, 2004. Available at: http://www.fda.gov. Accessed November 18, 2004.

Advance Data From Vital and Health Statistics. Number 342. Centers for Disease Control and Prevention. May 21, 2004. 2002 National Hospital Discharge Survey. Available at: http://www.cdc.gov. Accessed November 18, 2004.

The State of the Art in the Management of Osteoporosis: Highlights from a Scientific Roundtable Held July 2003, Washington, DC. Presented by The Office on Women's Health of the U.S. Department of Health and Human Services. http://www.4woman.gov. Accessed November 18, 2004.

"BMD Testing: What the Numbers Mean." National Osteoporosis Foundation. http://www.nof.org. Accessed November 18, 2004.

"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis." N Engl J Med. 2004;350(5):459-68.

"Prevention: Calcium Supplements." National Osteoporosis Foundation. http://www.nof.org. Accessed November 18, 2004.

"Pharmacokinetics of calcium absorption from two commercial calcium supplements." Heller, HJ, et al. Journal of Clinical Pharmacology. 1999; 39:1151-1154.Turner LW, Bass MA, Ting L, Brown B. Influence of yard work and weight training on bone mineral density among older U.S. women. J Women Aging. 2002; 14(3-4):138-48.

"FDA Approves Lower Dose of Prempro, A Combination Estrogen and Progestin Drug for Postmenopausal Women." Press Release, March 13, 2003. http://www.fda.gov. Accessed November 18, 2004.

"FDA Approves New Labels for Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women Following Review of Women's Health Initiative Data." FDA News/Press Release. January 8, 2003. http://www.fda.gov. Accessed November 18, 2004.

Lacey, James V., et al. "Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer." JAMA 2002. Vol. 288:334-341.368-369.

Marchbanks, P.A, et al. "Oral Contraceptives and the Risk of Breast Cancer" NEJM 2002. Vol. 346:2025-2032, No. 26

Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Heart and estrogen/progestin replacement study follow-up (HERS II): Part 1. Cardiovascular outcomes during 6.8 years of hormone therapy. JAMA 2002;288:49-57.

Hulley S, Furberg C, Barrett-Connor E, et al, for the HERS Research Group. Heart and estrogen/progestin replacement study follow-up (HERS II): Part 2. Non-cardiovascular outcomes during 6.8 years of hormone therapy. JAMA 2002;288:58-66.

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.

"Estrogen Plus Progestin Study Stopped Due to Increased Breast Cancer Risk, Lack of Overall Benefit." National Heart, Lung and Blood Institute. http://www.nhlbi.nih.gov. July 9, 2002. Accessed November 18, 2004.

Women's Health Initiative. National Heart, Lung and Blood Institute. http://www.nhlbi.nih.gov. Accessed November 18, 2004.

Cauley JA, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). The American Journal of Medicine. April 15, 2001. Vol. 110(6), pp. 442-450.

"Osteoporosis Overview" and "Specific Topics in Osteoporosis." National Institutes of Health: Osteoporosis and Related Bone Diseases-- National Resource Center. Revised August 2004 http://www.osteo.org. Accessed November 18, 2004.

"Frequently Asked Questions on Alcohol Abuse and Alcoholism." National Institute on Alcohol Abuse and Alcoholism. Updated May 14, 2002. http://www.niaaa.nih.gov. Accessed November 18, 2004.

"Osteoporosis: Fight Back & Be Strong." The National Women's Health Report. National Women's Health Resource Center. Feb. 1999.

"Osteoporosis: Progress and Promise." National Institute of Arthritis and Musculoskeletal and Skin Diseases. August 2000. http://www.nih.gov. Accessed November 18, 2004.

Shapiro, C.L., et al. Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer. J Clin Oncol 2001 19: 3306-11. http://www.jco.org. Accessed November 18, 2004.

Torgerson, DJ, Bell-Syer SE. The Journal of the American Medical Association. Hormone Replacement Therapy and Prevention of Nonvertebral Fractures: A Meta-analysis of Randomized Trials. June 13, 2001. Vol. 285, pp. 2891-2897, 2909-2910.

U. S. Food and Drug Administration: Center for Drug Evaluation and Research. http://www.fda.gov. Accessed November 18, 2004.

Weaver, C. M., et al. Impact of exercise on bone health and contraindication of oral contraceptive use in young women. Med. Sci. Sports Exerc., Vol. 33, No. 6, 2001, pp. 873-80. http://www.ms-se.com. Accessed November 18, 2004.

Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis: 2001 Edition, with Selected Updates for 2003. American Association of Clinical Endocrinologists. http://www.aace.com. Accessed November 18, 2004.

"FDA Approves Teriparatide to Treat Osteoporosis." FDA Talk Paper. November 16, 2002. . http://www.fda.govAccessed November 18, 2004.

"Bone Loss in Premenopausal Women with Depression" National Institute of Mental Health. ClinicalTrials.gov. Updated July 13, 2003. http://clinicaltrials.gov. Accessed November 18, 2004.

"Fast Facts." National Osteoporosis Foundation. Updated Feb. 2003. http://www.nof.org. Accessed November 18, 2004.

"Drug Details: Menostar (Brand Name Drug)." U.S. Food & Drug Administration, Center for Drug Evaluation and Research, http://www.accessdata.fda.gov. Accessed November 18, 2004.

"Study of Tamoxifen and Raloxifene Trial (STAR)." The National Cancer Institute. Updated April 26, 2006. http://www.cancer.govr. Accessed May 2006.